King Luther Capital Management Corp Buys Shares of 36,347 Prestige Consumer Healthcare Inc. $PBH

King Luther Capital Management Corp purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 36,347 shares of the company’s stock, valued at approximately $2,268,000. King Luther Capital Management Corp owned approximately 0.07% of Prestige Consumer Healthcare at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PBH. Caitong International Asset Management Co. Ltd grew its stake in Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at about $32,000. Hantz Financial Services Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 373.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after buying an additional 538 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth approximately $46,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Prestige Consumer Healthcare by 294.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after acquiring an additional 447 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PBH has been the subject of several recent analyst reports. Jefferies Financial Group lowered their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group dropped their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $69.59 on Friday. The firm has a market capitalization of $3.29 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 2.17 and a beta of 0.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The company’s fifty day moving average price is $64.50 and its 200-day moving average price is $63.48.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue was down 2.4% on a year-over-year basis. During the same quarter last year, the business earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 2,000 shares of company stock worth $125,930 over the last three months. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).